|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Real-world safety and efficacy of glycoprotein Ⅱb/Ⅲ a inhibitors during percutaneous coronary intervention 显示文摘 | Casterella P J Revenaugh JR Burke JL | 2008 | J Invasive Cardiol2008，20，3： | 1 |
| 2 | Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study 显示文摘 | Bhatt DL Lee BI Casterella P J | 2003 | J Am Coil Cardiol2003，41，1： | 1 |
| 3 | Prevention of coronary restenosis 显示文摘 | Casterella PJ Teirstein PS | 1999 | Cardiol Rev1999，7，4： | 1 |
| 4 | Auditor industry specialization, client bargaining power, and audit prieing显示文摘 | Casterella J Francis J Lewis B | 2004 | Auditing: A Journal of Practice I: Theory2004，23，1： | 1 |
| 5 | Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovas- cular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinica| data, and recommended guideline revisions 显示文摘 | Casterella PJ Tcheng JE | 2008 | Am Heart J2008，155，5： | 1 |
| 6 | Is self-regulated peer review effective at signaling auditquality-显示文摘 | CASTERELLA J R JENSEN K L KNECHEL W R | 2009 | The Accounting Review2009，84，3： | 1 |
| 7 | Prevention of coronary restenosis显示文摘 | Casterella PJ Teirstein PS | 1999 | Cardiol Rev1999，7，： | 1 |
| 8 | Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention, results of the Coronary Revascularization, Using Integrilin and Single Bolus Enoxaparin Study显示文摘 | Bhatt DE Lee BI Casterella PJ | 2003 | J Am Coil Cardiol2003，41，： | 1 |
| 9 | Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study显示文摘 | Bhatt DL Lee BI Casterella PJ | 2003 | J Am Coll Cardiol2003，41，1： | 1 |
| 10 | Prevention of coronary restenosis 显示文摘 | Teirstein PS | 1999 | Cardiol Rev1999，7，： | 1 |
| 11 | Prevention of coronary restenosis显示文摘 | Casterella PJ Teirstein PS | 1999 | Cardiol Rev1999，7，4： | 1 |
| 12 | Prevention of coronry restenosis显示文摘 | Casterella PJ Teirstein PS | 1999 | Gardio Rev1999，7，4： | 1 |
| 13 | Prevention of coronary restenosis 显示文摘 | Casterella P J Teirstein P S | 1999 | Carcliol Rev1999，7，4： | 1 |
| 14 | Prevention of coronary vestensis显示文摘 | Casterella PJ Teirstein PS | 1999 | Cardiol Res1999，7，： | 1 |
| 15 | Auditor industry specialization,client bargaining power, and audit pricing显示文摘 | Casterella J R Franeis J R Lewis B L | 2004 | A Journal of Practice & Theory2004，23，1： | 1 |
| 16 | Auditor industry specialization, client bargaining power, and auditing pricing显示文摘 | Casterella J Francis J Lewis B | 2004 | Auditing: A Journal of Practice & Theory2004，23，1： | 1 |
| 17 | Prevention of coronary restenosis显示文摘 | Casterella PJ Teirstein PS | 1999 | Cardiol Rev1999，7，： | 1 |
| 18 | Prevention of coronary restenosis显示文摘 | Teirstein PS | 1999 | Cardiol Rev1999，7，4： | 1 |
| 19 | Prevention of coronary restenosis显示文摘 | Casterella PJ Teirstein PS | 1999 | Cardiol Rev1999，7，4： | 1 |
| 20 | Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions : practical implications, new clinical data,and recommended guideline revisions显示文摘 | Casterella PJ Tcheng JE | 2008 | Am Heart J2008，155，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员